Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study

Impact of Bevacizumab on Visual Function, Tumor Size, and Toxicity in Pediatric Progressive Optic Pathway Glioma: A Retrospective Nationwide Multicentre Study

Backgrounds: Bevacizumab (BVZ) is used as a subsequent line of treatment for pediatric optic pathway glioma (OPG) in the case of progression. Data on the treatment effect concerning tumor progression and visual function are scarce and nationwide studies are lacking. Methods: We performed a retrospec...

Full description

Bibliographic Details
Main Authors: Carlien A. M. Bennebroek, Judith van Zwol, Giorgio L. Porro, Rianne Oostenbrink, Anne T. M. Dittrich, Annabel L. W. Groot, Jan W. Pott, Etienne J. M. Janssen, Noël J. Bauer, Maria M. van Genderen, Peerooz Saeed, Maarten H. Lequin, Pim de Graaf, Antoinette Y. N. Schouten-van Meeteren
Format: Article
Language:English
Published: MDPI AG 2022-12-01
Series:Cancers
Subjects:
bevacizumab
optic pathway glioma
low grade glioma
child
systemic anticancer therapy
visual function
Online Access:https://www.mdpi.com/2072-6694/14/24/6087

Internet

https://www.mdpi.com/2072-6694/14/24/6087

Similar Items